Clinical Trial Update: A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) [Phase 2]

View source ↗

Summary

Phase 2 study of robatumumab in relapsed osteosarcoma or Ewing's sarcoma was terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Osteosarcoma
• Peripheral Neuroectodermal Tumor

Drugs mentioned

• robatumumab (robatumumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteosarcoma, Sarcoma, Ewing's | Phase 2 | Status: TERMINATED | Results posted: 2015-12-11